Change in amniotic fluid levels of multiple anti-angiogenic proteins before development of preeclampsia and intrauterine growth restriction.
BACKGROUND
The cause of preeclampsia remains unknown. Excessive antiangiogenic proteins have been proposed to play a pathogenic role in preeclampsia.


OBJECTIVE
Our objective was to determine the differences in soluble endoglin (sEndoglin), soluble fms-like tyrosine kinase receptor-1 (sFLT1), leptin, adiponectin, and endothelin 1 concentrations between normal and preeclampsia amniotic fluid (AF). Such results may help us understand the pathophysiology of preeclampsia.


METHODS
We performed a nested case-control study. Seventy-one women with preeclampsia were matched to 71 normotensive controls. The preeclamptic women were broken into two subgroups according to the association with fetal intrauterine growth restriction (IUGR). AF concentrations of sEndoglin, sFLT1, leptin, adiponectin, and endothelin 1 were measured by ELISA. Receiver-operating characteristics curve analysis was used to compare the discriminative values of these potential biomarkers. Functional network analysis was performed using MetaCore to reveal the common functions of the interacting proteins.


RESULTS
Increased AF concentrations of sFLT1, sEndoglin, endothelin 1, and leptin were found in women who later developed preeclampsia. sFLT1, sEndoglin, leptin, and adiponectin were significantly higher in the preeclampsia with IUGR than those without IUGR. Leptin has the largest area under the curve (0.753). Network analysis revealed that elevated amniotic proteins are involved in the inflammatory process of the human placenta.


CONCLUSIONS
Significant elevation of leptin can be detected in AF 2 months earlier than the appearance of symptoms; thus, it may be used as a predictive marker for preeclampsia. The increase of these antiangiogenic proteins supports the roles of inflammation and oxidative stress in pathogenesis of preeclampsia.
Wang
Chao-Nin
CN
No.5, Fu-Shin Road, Gwei-Shan, Tao-Yuan 333, Taiwan.
Chang
Shuenn-Dyh
SD
Peng
Hsiu-Huei
HH
Lee
Yun-Shien
YS
Chang
Yao-Lung
YL
Cheng
Po-Jen
PJ
Chao
An-Shine
AS
Wang
Tzu-Hao
TH
Wang
Hsin-Shih
HS
D052242:Adiponectin / Q000032:analysis; D000328:Adult; D000653:Amniotic Fluid / Q000737:chemistry*; D000704:Analysis of Variance; D015703:Antigens, CD / Q000032:analysis; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D000071063:Endoglin; D019332:Endothelin-1 / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005317:Fetal Growth Retardation / Q000378:metabolism*; D006801:Humans; D020738:Leptin / Q000032:analysis; D011225:Pre-Eclampsia / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism; D011237:Predictive Value of Tests; D011247:Pregnancy; D011446:Prospective Studies; D012372:ROC Curve; D011956:Receptors, Cell Surface / Q000032:analysis; D012044:Regression Analysis; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000032:analysis
D052242:Adiponectin; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D019332:Endothelin-1; D020738:Leptin; D011956:Receptors, Cell Surface; D040281:Vascular Endothelial Growth Factor Receptor-1